NCT00612014已完成2 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-ranging Study to Assess the Efficacy and Safety of TZP-101 When Administered as a 30 Minute I.V. Infusion to Subjects With Severe Gastroparesis Due to Diabetes Mellitus
Tranzyme, Inc.12 个研究点 分布在 6 个国家目标入组 78 人开始时间: 2007年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 78
- 试验地点
- 12
- 主要终点
- Change from baseline in the mean Gastroparesis Cardinal Symptom Index score (24 hour recall version) across the four days of dosing. Baseline is the average of the scores collected across the 4 days just prior to admission for dosing.
研究概览
简要总结
The purpose of this study is to determine whether TZP-101 is effective in the treatment of symptomatic gastroparesis due to diabetes.
详细描述
Subjects are randomized according to an adaptive randomization procedure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has type 1 or type 2 diabetes mellitus
- •Subject has documented diagnosis of gastroparesis (all of the following apply):
- •Confirmed delayed gastric emptying (see Appendix IV; properly conducted gastric emptying assessments within last 6 months acceptable)
- •AND a minimum 3 month history of relevant symptoms for gastroparesis (chronic postprandial fullness, bloating, epigastric discomfort, early satiety, belching after meal, postprandial nausea, vomiting).
- •AND a mean Gastroparesis Cardinal Symptom Index (GCSI) Score (2 week recall version) of ≥ 2.66
- •AND it is confirmed by endoscope that there are no obstructive lesions in the esophagus or stomach (endoscopy within prior 3 months acceptable)
- •Subject has never had a gastrectomy, nor major abdominal surgery or any evidence of bowel obstruction within the previous 12 months
- •Dosage of any concomitant medications has been stable for at least 3 weeks
- •HbA1c level is ≤ 10.0%
- •Subject has a BMI < 30
- •Subject body weight is ≤ 100 kg
- •If female, post-menopausal for the past 12 months, surgically sterile (i.e. tubal ligation, hysterectomy), or using an adequate method of birth control (i.e., oral contraceptives, double barrier method, IUD cover) or sterilized partner
排除标准
- •Subject has acute severe gastroenteritis
- •Subject has a gastric pacemaker
- •Subject is on chronic parenteral feeding
- •Subject has daily persistent severe vomiting
- •Subject has pronounced dehydration
- •Subject has had diabetic ketoacidosis in last 4 weeks
- •Subject has a history of eating disorders (anorexia nervosa, binge eating, bulimia)
- •Subject has a marked baseline prolongation of QT/QTc interval (repeated demonstration of a QTc interval >450 ms for male / >470 ms for female)
- •Subject has a history of additional risk factors for Torsades de Pointes (heart failure, chronic hypokalemia, family history of Long QT Syndrome)
- •Subject requires use of concomitant medication that prolongs the QT interval
- •List provided to clinical sites
- •Subject has history of cardiovascular ischemia in previous 12 months or acute myocardial infarction (MI) or unstable angina
- •Subject requires use of concomitant medication that is known to interact with isoenzyme CYP3A4 and the combination with an CYP3A4 inhibitor is known to introduce a clinically significant drug interaction
- •List provided to clinical sites
- •Subject has a history of psychiatric disorder or cognitive impairment that would interfere with participation in the study
- •Subject has a history of alcoholism
- •Subject is taking regular daily narcotics
- •Subject has a known history of Hep B, Hep C or HIV
- •Subject has severely impaired renal function (creatinine clearance < 30 mL/min)
- •Subject has severe impairment of liver function, defined as albumin level ≤ 2.5 gm/dL and/or prothrombin time >6 seconds over control (INR > 2.3)
- •Subject has participated in an investigational study within 30 days prior to or received TZP-101 within 90 days prior to study initiation
- •Subject is pregnant or is breast-feeding
研究组 & 干预措施
1
Placebo Comparator
干预措施: 5% dextrose in water (Drug)
2
Experimental
40 micrograms/kg
干预措施: TZP-101 (Drug)
3
Experimental
80 micrograms/kg
干预措施: TZP-101 (Drug)
4
Experimental
160 micrograms/kg
干预措施: TZP-101 (Drug)
5
Experimental
320 microgram/kg
干预措施: TZP-101 (Drug)
6
Experimental
600 microgram/kg
干预措施: TZP-101 (Drug)
结局指标
主要结局
Change from baseline in the mean Gastroparesis Cardinal Symptom Index score (24 hour recall version) across the four days of dosing. Baseline is the average of the scores collected across the 4 days just prior to admission for dosing.
时间窗: after 4 dosing days
次要结局
- Cumulative GSA score after each dosing event and after all dosing events(every 30 minutes for 4 hours)
研究者
研究点 (12)
Loading locations...
相似试验
终止
2 期
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102Diabetic GastroparesisNCT01664637Tranzyme, Inc.120
已完成
1 期
Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Diabetic GastroparesisDiabetes MellitusGastroparesisNCT00639808Tranzyme, Inc.10
已完成
2 期
Safety and Efficacy of IV Infusion of TZP-101 for POI After Major Open Abdominal SurgeryPostoperative IleusNCT00617552Tranzyme, Inc.267
撤回
2 期
A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal WomenHip FractureNCT00787358Zelos Therapeutics50
已完成
3 期
A Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel ResectionPostoperative IleusNCT01710982Norgine27